Regulator says too many drugmakers chasing same cancer strategy

CHICAGO (Reuters) – A new type of cancer drug that takes the brakes off the body’s immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S. regulator says too many companies are focused on the same approach.

Leave a Reply

Read the original at Reuters: Science News.